The Nicotinic Alpha3Alpha6Beta2 Receptor: A Potential Drug Target

Target Name: Nicotinic alpha3alpha6beta2 Receptor

NCBI ID: P38078

Nicotinic alpha3alpha6beta2 Receptor

Other Name(s): Cholinergic receptor nicotinic alpha3alpha6beta2 | nAChR alpha3alpha6beta2 | Nicotinic cholinergic receptor alpha3alpha6beta2

The Nicotinic Alpha3Alpha6Beta2 Receptor: A Potential Drug Target

The Nicotinic Alpha3Alpha6Beta2 Receptor (Cholinergic Receptor Nicotinic Alpha3Alpha6Beta2) is a transmembrane protein that plays a crucial role in cellular signaling. It is a G protein-coupled receptor (GPCR), which means it interacts with intracellular signaling molecules known as G proteins. The alpha3alpha6beta2 subunit of the Nicotinic Alpha3Alpha6Beta2 Receptor is a key protein that has been extensively studied for its role in various physiological processes, including neurotransmission, pain perception, and addiction.

The alpha3alpha6beta2 subunit of the Nicotinic Alpha3Alpha6Beta2 Receptor is composed of 484 amino acid residues and has a calculated molecular weight of 59.1 kDa. It consists of an extracellular region (ECR), a transmembrane region (TM), and an intracellular region (ICR). The ECR is the region that interacts with the G protein-coupled receptor signaling pathway, while the TM and ICR are involved in the internal signaling processes.

The alpha3alpha6beta2 subunit of the Nicotinic Alpha3Alpha6Beta2 Receptor has several unique features that make it an attractive drug target. First, it has a high degree of homogeneity, which means that it has the same number of amino acids at all its residues. Second, it has a large transmembrane region, which allows for a large molecule to interact with a variety of intracellular signaling molecules. Third, it has a unique binding site that is specific for G proteins, which makes it a good candidate for a GPCR.

The alpha3alpha6beta2 subunit of the Nicotinic Alpha3Alpha6Beta2 Receptor has been the focus of extensive research because of its role in various physiological processes. One of the most well-studied functions of the alpha3alpha6beta2 subunit is its role in neurotransmission. The alpha3alpha6beta2 subunit is involved in the regulation of neurotransmitter release from neurons, which is critical for the function of the nervous system.

In addition to its role in neurotransmission, the alpha3alpha6beta2 subunit of the Nicotinic Alpha3Alpha6Beta2 Receptor is also involved in pain perception and addiction. Studies have shown that the alpha3alpha6beta2 subunit is involved in the regulation of pain perception and that it may play a role in the development of addiction.

The alpha3alpha6beta2 subunit of the Nicotinic Alpha3Alpha6Beta2 Receptor has also been identified as a potential drug target. Studies have shown that the alpha3alpha6beta2 subunit can be targeted by small molecules, such as inhibitors of G protein-coupled receptor signaling pathway, which could be useful for treating various diseases.

In conclusion, the Nicotinic Alpha3Alpha6Beta2 Receptor (Cholinergic Receptor Nicotinic Alpha3Alpha6Beta2) is a transmembrane protein that plays a crucial role in cellular signaling. The alpha3alpha6beta2 subunit of the Nicotinic Alpha3Alpha6Beta2 Receptor is a key protein that has been extensively studied for its role in various physiological processes, including neurotransmission, pain perception, and addiction. The alpha3alpha6beta2 subunit is also a potential drug target, and its properties make it an attractive target for small molecule inhibitors of G protein-coupled receptor signaling pathway.

Protein Name: Nicotinic Alpha3alpha6beta2 Receptor

The "Nicotinic alpha3alpha6beta2 Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Nicotinic alpha3alpha6beta2 Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets